PAIN AID ESF- (Acetaminopehn USP 250mg, Asprin USP 250mg Caffeine 65mg) coated, bulk OTC tablets packaged in corrugated boxes lined with 2 polyethylene bags 100 lb, ULTRAtab Laboratories, Inc. NDC# 62959-560-00, Product Code M560L

CGMP Deviations: failed stability results, inadequate laboratory investigations,

Recall #: D-0327-2022
Affected scope: 14 bulk lots (approximately 1,987,951 tablets each)
Initiated: November 29, 2021

Compiled from official public sources by the publisher. · Updated September 2026

ULTRAtab Laboratories, Inc. recalled PAIN AID ESF- (Acetaminopehn USP 250mg, Asprin USP 250mg Caffeine 65mg) coated, bulk OTC … - a moderate-severity action.

PAIN AID ESF- (Acetaminopehn USP 250mg, Asprin USP 250mg Caffeine 65mg) coated, bulk OTC … was recalled by ULTRAtab Laboratories, Inc. in January 12, 2022. Reason: CGMP Deviations: failed stability results, inadequate laboratory investigations,. Check the official notice for the remedy. Verify recall #D-0327-2022 with the FDA Drug before acting.

The recall

ULTRAtab Laboratories, Inc. issued this moderate-severity FDA Drug recall-CGMP Deviations: failed stability results, inadequate laboratory investigations,.

Moderate
severity level: Class II
classification: January 12, 2022
reported

Sourced from official FDA Drug enforcement records. Verify recall #D-0327-2022 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.

Recall Insight

This recall's affected scope, documented in the Recall Profile below, stays within a single-region or limited-distribution footprint. Distribution scope (see Distribution below) directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.

Within the same product category the archive holds 6 closely related recalls, 6 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.

Where this agency-classified recall sits among FDA Class I/II/III notices

Of 88,244 recalls with an agency hazard classification, 19,068 are high severity, 64,652 moderate, and 4,524 low. A further 16,179 CPSC/NHTSA recalls have no agency class and are excluded from this split. This recall is classified moderate severity.

Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.

Product description

Reason for recall

CGMP Deviations: failed stability results, inadequate laboratory investigations,

Recall Profile

Structured summary of the FDA Drug recall record
Attribute	Value
Agency	U.S. Food and Drug Administration
Severity class	Moderate (Class II)
Status	Terminated
Recall number	D-0327-2022
Date reported	January 12, 2022
Date initiated	November 29, 2021
Recalling firm	ULTRAtab Laboratories, Inc.
Firm location	Highland, NY
Affected scope	14 bulk lots (approximately 1,987,951 tablets each)
Distribution	Product was distributed to one customer who may have further distributed the product.

Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.

What to do with this recall

Match your product against the recall record, then act on the agency remedy.

Check the recall number (D-0327-2022) and product description against the item you own. Search the archive
Confirm the current status with FDA Drug before acting, recall details can be updated.
Follow the documented remedy (refund, replacement, repair, or disposal) rather than general advice. What to do next

This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.

Frequently Asked Questions

What product was recalled? ▼

PAIN AID ESF- (Acetaminopehn USP 250mg, Asprin USP 250mg Caffeine 65mg) coated, bulk OTC tablets packaged in corrugated boxes lined with 2 polyethylene bags 100 lb, ULTRAtab Laboratories, Inc. NDC# 62959-560-00, Product Code M560L. Recalled by ULTRAtab Laboratories, Inc.. Units affected: 14 bulk lots (approximately 1,987,951 tablets each).

Why was this product recalled? ▼

CGMP Deviations: failed stability results, inadequate laboratory investigations,

Which agency issued this recall? ▼

This recall was issued by the FDA Drug on January 12, 2022. Severity: Moderate. Recall number: D-0327-2022.

Where was the recalled product distributed? ▼

Distribution: Product was distributed to one customer who may have further distributed the product..

Should I stop using a recalled medication or medical device? ▼

Do not stop using a recalled medication or device without consulting your healthcare provider first, as abruptly discontinuing treatment could pose its own health risks. Your doctor can advise on alternatives or whether the recall applies to your specific product lot. Check the recall number and lot information against your product packaging.

Nationwide recalls with similar severity or category timing

Drug and device notices outside this firm and state, matched by severity timing and product category.

Similar severity · nearest report date

Same archive severity grade (Moderate), closest by report date among other firms and states.

Giant Bicycle Recalls Bicycles Due to Fal… 2022-01-12 EGL Motor Recalls Youth All-Terrain Vehic… 2022-01-12 Children's Robes Recalled by HulovoX Due … 2022-01-12 EQUALINE aller-ease fexofenadine hydrochl… 2022-01-12

Similar Drugs & Medications · nearest report date

Same product category, closest by report date among other firms and states (deduped against the severity set).

Gatifloxacin Ophthalmic Solution, 0.5%, 2… 2022-01-12 Oxycodone Hydrochloride Tablets, USP C-II… 2022-01-12 Cefixime Capsules, 400 mg, 50-count bottl… 2022-01-12 Cefixime 400 mg capsule, packaged in a) 2… 2022-01-12

Compare this recall with Kian Pee Wan Capsules, 30-count bottles → · All Drugs & Medications recalls

This recall: FDA Drug, reported January 12, 2022. Severity classes follow each agency's own taxonomy; related-recall context is computed across the full archive.

Methodology · Corrections · Archive as of August 2026